STOCK TITAN

Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Codexis, Inc. (CDXS) will report its financial results for Q4 and FY 2023 on February 28, 2024. The company will host a conference call to discuss the results and provide a business update.
Positive
  • None.
Negative
  • None.

REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2023 on Wednesday, February 28, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.

Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.

About Codexis
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit www.codexis.com.

For More Information

Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com

Media Contact
Lauren Musto
(650) 421-8205
media@codexis.com

 


Codexis, Inc. (CDXS) will report its financial results for the fourth quarter and fiscal year 2023 on Wednesday, February 28, 2024.

The conference call and webcast will be held at 4:30 pm Eastern Time.

Participants may access the live webcast on the Codexis Investor Relations website.

The webcast will be archived for 90 days on the Codexis Investor Relations website.

The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international).

A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.
Codexis Inc.

NASDAQ:CDXS

CDXS Rankings

CDXS Latest News

CDXS Stock Data

Paint and Coating Manufacturing
Manufacturing
Link
Process Industries, Chemicals: Specialty, Manufacturing, Paint and Coating Manufacturing
US
Portland

About CDXS

codexis, inc. is a leading protein engineering company applying innovative technologies to unlock the power of proteins™. our proprietary codeevolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. codexis’ revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. you get precisely the protein you need for the job you want it to do. guided by proprietary artificial intelligence software and advanced high-throughput screening systems, codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. since 2002, codexis’ in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough develop